Is Rybelsus Being Discontinued? What Happened and the Ozempic Pill Switch

Yes, in the United States. Novo Nordisk told the FDA it is ending manufacture of all three Rybelsus strengths (14, 7 and 3 mg), and the FDA posted the discontinuation on June 4, 2026 with one line of explanation: “These products will be replaced by Ozempic (semaglutide) tablets.”^[2] The medicine itself has not gone anywhere. Ozempic tablets are the same semaglutide, reformulated into lower-milligram 1.5, 4 and 9 mg pills, and they have been on sale since May 4, 2026.^[4] The two names now share one FDA label, with the same uses and the same warnings.^[1] Nothing in the FDA posting or in Novo’s statements points to a safety problem.

What happened to Rybelsus, in order

Novo Nordisk announced the new name on February 4, 2026. The FDA had approved the 1.5, 4 and 9 mg formulation on the strength of a bioequivalence study plus the clinical trials already run on Rybelsus at its 3, 7 and 14 mg strengths, and that month it approved Ozempic as the brand name for it. The company told Rybelsus patients to keep taking their medicine and not to stop without talking to their prescriber.^[3] Its May 1 release set the launch for Monday, May 4, and described the change plainly: the original strengths “have been reformulated” and are now sold as Ozempic tablets.^[4]

The supply side shows up in a notice Illinois sent its Medicaid prescribers on May 21, 2026. It says Novo informed the state that it would discontinue every Rybelsus strength, that shipments to wholesalers would stop beginning in May, and that existing inventory was expected to become limited from July 2026.^[5] The FDA entry followed on June 4. It lists each Rybelsus bottle by NDC number and gives the reason as “Discontinuation of the manufacture of the drug.”^[2]

Was Rybelsus pulled for safety reasons?

No. The FDA posting gives the end of manufacture as its reason and names the replacement.^[2] The FDA’s recall database has no Rybelsus recall in 2026. Its only Rybelsus entry is a Class II recall from March 2021 of 7 mg blister packs exposed to temperature swings in storage, and that recall is closed.^[10] Novo describes the new tablet as having the same efficacy and safety profile as the original, in a smaller pill.^[4] That is Novo’s wording.

The label is identical for both names. Rybelsus and Ozempic tablets carry two uses in adults with type 2 diabetes. One is improving blood sugar, alongside diet and exercise. The other, for patients at high risk, is cutting the chance of a heart attack, a stroke or death from cardiovascular causes.^[1] That second use rests on the SOUL trial, which randomized 9,650 people to the 14 mg Rybelsus tablet or placebo. Over a median of about four years, a major cardiovascular event occurred in 12.0% on the tablet and 13.8% on placebo, a hazard ratio of 0.86.^[6] An earlier safety trial, PIONEER 6, enrolled 3,183 people and met its goal of showing the tablet did not raise cardiovascular risk.^[7] The boxed warning about thyroid C‑cell tumors in rodents applies to both names.^[1]

How Ozempic tablets differ from Rybelsus

The molecule and the absorption enhancer, SNAC, are the same. What changed is how much of each dose reaches the blood. The label puts absolute bioavailability at about 0.4% to 1% for the Rybelsus tablets and 1% to 2% for Ozempic tablets, which is why the new pills carry fewer milligrams.^[1] In a study in healthy volunteers, steady-state exposure from the 3, 7 and 14 mg Rybelsus doses showed no clinically significant difference from the 1.5, 4 and 9 mg Ozempic tablet doses.^[1]

Taking the pill has not changed. Either tablet is swallowed whole at the start of the day, stomach empty, with plain water up to 4 ounces, and food, other drinks and other oral medicines wait at least 30 minutes.^[1] The Ozempic tablet carton carries a note to the pharmacist that strengths of semaglutide “are not substitutable on a mg-to-mg basis” and marks the product as a new formulation.^[1]

Rybelsus to Ozempic pill conversion: what the label says

The label opens its dosing section with the warning that the two products “are not substitutable on a mg-to-mg basis,” and its switching table pairs a 9 mg Ozempic tablet with a 14 mg Rybelsus tablet.^[1] A 14 mg dose of the new formulation does not exist, and taking milligrams across from one product to the other would be a mistake.

The 3 mg and 1.5 mg tablets are starter doses only. The label says each “is not effective for glycemic control” and is meant for the first 30 days, after which the dose steps up.^[1] Someone who began on Rybelsus 3 mg finishes those 30 days before moving to an Ozempic tablet maintenance dose, which is how the Illinois notice relays Novo’s guidance too.^[5] Anyone starting fresh now begins on Ozempic 1.5 mg.^[5] The label’s injection-to-pill instructions cover only people on the 0.5 mg Ozempic pen.^[1]

Because the strengths differ, the pharmacy cannot simply fill a Rybelsus prescription with Ozempic tablets. Illinois Medicaid, for example, does not convert patients automatically: a new prescription is needed, and so is a new prior authorization.^[5] Commercial plans write their own rules, so check with yours. The FDA posting covers the 3 mg and 7 mg bottles as well as the 14 mg, all on the same date.^[2]

What the switch means for coverage and cost

Novo says Ozempic tablets will be covered by insurance for most people with type 2 diabetes, and that with its savings offer a commercially insured patient may pay $25 or less for a supply of up to three months.^[4] NovoCare caps that savings at $100 a month.^[9] At launch the company listed self-pay prices through NovoCare Pharmacy and some telehealth services of $149 a month for the 1.5 mg starter dose, with the 4 mg pill at $199 and the 9 mg pill at $299, with government beneficiaries excluded from the offer.^[4] In October 2026 NovoCare still advertised the Ozempic pill from $149 a month.^[9] Our Rybelsus drug page and the Rybelsus vs Ozempic comparison cover the injection side of the decision.

Ozempic pill, Wegovy pill and Rybelsus: three names

The rename created a near-twin. The Wegovy pill’s label lists semaglutide tablets in 1.5, 4, 9 and 25 mg strengths, licensed for weight reduction and for lowering cardiovascular risk in adults who already have heart disease along with obesity or overweight.^[8] Ozempic tablets come in 1.5, 4 and 9 mg and are licensed for type 2 diabetes.^[1] Neither label says the two are the same product, and the Wegovy label advises against combining it with any other semaglutide product.^[8] Our Ozempic pill explainer sets the two side by side with Foundayo. For what the weight-loss pill costs, see Wegovy pill cost. For how any oral semaglutide compares with the weekly shot, see is the pill as good as the shot, and for what the Rybelsus trials showed on weight, see Rybelsus for weight loss.

A 25 mg Ozempic tablet is not on the label yet. Novo filed for one in early 2026 and said it expected an FDA decision by the end of the year.^[3][4] The change is limited to the US. Novo says Rybelsus “will continue to be marketed outside the US.”^[4] Readers checking whether a pill is a GLP‑1 at all can use our list of GLP‑1 drugs.